Johnson & Johnson (JNJ) Rolls to New Highs After Drug Results

Johnson & Johnson (NYSE:JNJ) is trading at all-time highs, yet there's still pessimism lingering on Wall Street

Jun 6, 2016 at 10:28 AM
facebook X logo linkedin


Unlike some of its smaller sector peers, blue-chip stock Johnson & Johnson (NYSE:JNJ) is continuing its strong year-to-date performance today, adding 0.8% at $115.72, and earlier hitting a record high of $115.80, thanks to positive drug data. Specifically, patients receiving JNJ's drug for advanced multiple myeloma, Darzalex, combined with two other standard treatments, had better outcomes in a late-stage trial than those who received only the two other treatments. What's more, the company's Janssen Pharmaceuticals unit has entered into a research agreement with Amyris Inc (NASDAQ:AMRS). All in all, JNJ stock is now up 12.7% in 2016, which should be good news for options traders. 

Specifically, JNJ's 10-day call/put volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in at 3.14, meaning call buying has more than tripled put buying in the past two weeks. Moreover, this reading sits just 2 percentage points from an annual high, showing an unusual call-bias among JNJ options traders. 

Digging deeper, peak open interest of more than 36,000 contracts resides at the front-month June 115 call. The stock's ability to power through this call-heavy level suggests not only impressive underlying strength, but also the potential for the shares to continue rising in the near term. 

There's still a decent bit of pessimism surrounding JNJ, too, that could help the stock move even higher. For starters, short sellers control almost four days' worth of pent-up buying power, at the stock's average pace of trading, despite a 20.6% drop in short interest during the last two reporting periods. Additional short covering could serve as a near-term boon.

What's more, half of the analysts covering Johnson & Johnson (NYSE:JNJ) say it's a "hold" or worse. JNJ stock could get a boost if this pessimism begins to unwind, in the form of future upgrades.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI